RE Voll

Learn More
The clinically approved proteasome inhibitor bortezomib (Bz) represents a promising agent for the therapy of relapsed multiple myeloma. However, long-term remissions are difficult to achieve, in fact myeloma cells often develop secondary resistance to proteasome inhibition. We recently demonstrated that myeloma cells are highly sensitive towards proteasome(More)
To date, the pathogenesis of systemic lupus erythematosus (SLE) is only partially understood. A characteristic feature of this disease is the occurrence of antibodies against nuclear antigens. Further, SLE is characterized by a type-I interferon gene signature. A dysregulation of apoptosis and phagocytosis of apoptotic cells is discussed as a central(More)
  • 1